Literature Highlights - November 2024

Keywords:

systemic lupus erythematosus, randomized clinical trial, belimumab, disease activity, patient-reported outcomes, disease trajectories, Efficacy, Iberdomide, Phase 2, Safety, CLE,, SLE, Type 2 diabetes, Cardiovascular, Renal, SGLT2i

LinkedIn